PF-184563 is a potent, selective non-peptidic antagonist of the V1a receptor. The compound was discovered by Pfizer in its Sandwich, Kent research center, as a potential treatment for dysmenorrhoea, an indication for which V1a antagonists have shown efficacy.
| Property | Value |
|---|---|
| dbo:abstract |
|
| dbo:bioavailability |
|
| dbo:casNumber |
|
| dbo:chEMBL |
|
| dbo:thumbnail | |
| dbo:wikiPageID |
|
| dbo:wikiPageLength |
|
| dbo:wikiPageRevisionID |
|
| dbo:wikiPageWikiLink | |
| dbp:atcPrefix |
|
| dbp:bioavailability |
|
| dbp:c |
|
| dbp:casNumber |
|
| dbp:chembl |
|
| dbp:chemspiderid |
|
| dbp:cl |
|
| dbp:eliminationHalfLife |
|
| dbp:h |
|
| dbp:iupacName |
|
| dbp:molecularWeight |
|
| dbp:n |
|
| dbp:proteinBound |
|
| dbp:smiles |
|
| dbp:stdinchi |
|
| dbp:stdinchikey |
|
| dbp:verifiedfields |
|
| dbp:verifiedrevid |
|
| dbp:watchedfields |
|
| dbp:width |
|
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| gold:hypernym | |
| rdf:type |
|
| rdfs:comment |
|
| rdfs:label |
|
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:depiction | |
| foaf:isPrimaryTopicOf | |
| is dbo:wikiPageRedirects of | |
| is dbo:wikiPageWikiLink of | |
| is foaf:primaryTopic of |
